Author(s): Ali Husain Shilib Al-Shimmery, Ahmed Abdul-Abbas Bayram, RaheemTuama Obayes Al Mammori, Noor S.K. Al-Khafaji, Hussein O.M. Al-Dahmoshi

Email(s): alishilb@yahoo.com , ahmedbayramgit@gmail.com , immunoraheem@yahoo.com , noorvaccince@gmail.com , dr.dahmoshi83@gmail.com

DOI: 10.52711/0974-360X.2022.00830   

Address: Ali Husain Shilib Al-Shimmery1, Ahmed Abdul-Abbas Bayram2, RaheemTuama Obayes Al Mammori3, Noor S.K. Al-Khafaji4, Hussein O.M. Al-Dahmoshi5
1Subspecialty Physician in GIT and Hepatology, Babylon GIT Center , Hilla City-Iraq.
2Subspecialty Physician in GIT and Hepatology, Babylon GIT Center , Hilla City-Iraq.
3Subspecialty in Clinical Immunology, Babylon GIT Center, Hilla City-Iraq.
4Assistant Prof., Department of Biology, College of Science, University of Babylon, Hilla City-Iraq.
5Assistant Prof., Department of Biology, College of Science, University of Babylon, Hilla City-Iraq.
*Corresponding Author

Published In:   Volume - 15,      Issue - 11,     Year - 2022


ABSTRACT:
Hepatitis can be defined as one of the liver’s inflammations that might be caused via viral infections, toxins, drugs and alcohol. The hepatitis via viral infection can be classified according to the type of viral strain and symptom into (A, B, C, D, E), the Hepatitis B is specified as one of the dangerous diseases resulting from a virus that is infecting the liver and has the ability of causing life-long infection, liver failure, liver cancer, cirrhosis (liver scarring) and death. The current work is carried out for evaluating the interferon as well as antiviral treatment effect on the viral load and viral activity among certain group of Hepatitis B virus infected patients enrolled to GIT and liver center in Merjan Medical City using Real time PCR for viral load and viral copy number determination. The results show that the all recorded cases in GIT center about (3612 hepatitis virus at both B and C), 2226 for HBV and 1386 for HCV, only 566 HBV patients was analysis by PCR around the year 2016. The males were high significant than females in hepatitis B infections. The north area of Babylon province had higher percentage than south and middle areas. Low activity of treatment protocol was mentioned on HBV infected patients, where (38.62 %) of patients had final outcome as undetectable viral load after treatment with combined interferon and oral anti–viral drugs. Conclusion: was that the combination treatment of immunological derivative and oral treatment more effective than single treatment used in HBV infection.


Cite this article:
Ali Husain Shilib Al-Shimmery, Ahmed Abdul-Abbas Bayram, RaheemTuama Obayes Al Mammori, Noor S.K. Al-Khafaji, Hussein O.M. Al-Dahmoshi. Combined Interferon-Antiviral therapy effectiveness against Hepatitis B viral infection in Babylon Province. Research Journal of Pharmacy and Technology. 2022; 15(11):4940-4. doi: 10.52711/0974-360X.2022.00830

Cite(Electronic):
Ali Husain Shilib Al-Shimmery, Ahmed Abdul-Abbas Bayram, RaheemTuama Obayes Al Mammori, Noor S.K. Al-Khafaji, Hussein O.M. Al-Dahmoshi. Combined Interferon-Antiviral therapy effectiveness against Hepatitis B viral infection in Babylon Province. Research Journal of Pharmacy and Technology. 2022; 15(11):4940-4. doi: 10.52711/0974-360X.2022.00830   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-11-15


REFERENCE:
1.    World Health Organization. Global hepatitis report 2017. World Health Organization; 2017.
2.    Al-Dahmoshi HO. Al-Saffar AK. Al-Khafaji NS. Ali JA. Muttaleb WH. Non invasive markers to predict liver damage among patients with chronic HBV, Hilla City-Iraq. International Journal of PharmTech Research. 2016; 9: 388-393.
3.    Rein DB. Stevens GA. Theaker J. Wittenborn JS. Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012; 55(4): 988-997. doi: 10.1002/hep.25505.
4.    Kumar RS. Basha SN. Nallasivan PK. SamSolomon WD. Venkatnarayanan R. Computer Aided Docking Studies on Antiviral Drugs for Bird Flu. Asian Journal Research in Chemistry 2010; 3(2): 370-373.
5.    Ali HY. Hepatitis B infection among Iraqi children: the impact of sanctions. EMHJ-Eastern Mediterranean Health Journal. 2004; 10(1-2): 6-11.  
6.    Al-Rubaye A. Tariq Z. Alrubaiy L. Prevalence of hepatitis B seromarkers and hepatitis C antibodies in blood donors in Basra, Iraq. BMJ open gastroenterology. 2016; 3(1): e000067. DOI:10.1136/bmjgast-2015-000067
7.    Singh UE. Mishra SK. Uike GPS., Singh AB. Gond S. Gupta J. Prevalence of HCV Infection in Healthy Donors of Rewa Division. Asian Journal Research in Chemistry 2015; 8(6): 407-412. DOI: 10.5958/0974-4150.2015.00067.X
8.    Jothivel N. Singaravel S. Deivasigamani K. Vasudevan M. Sundaram S. Sambasivam N. Thangavel S. Follow-Up of Combination of Chloroquine with Anti-Viral Drugs Treated Chronic Hepatitis ‘B’ Patients for Their Carrier State. Research Journal of Pharmacy and Technology 2008; 1(3): 259-259.
9.    Stanaway JD. Flaxman AD. Naghavi M. Fitzmaurice C. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. The Lancet. 2016; 388(10049): 1081-1088. doi: 10.1016/S0140-6736(16)30579-7
10.    Jiang X. Hiki N. Nunobe S. Kumagai K. et al. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. British Journal of Cancer. 2012; 107(2): 275-279. doi:10.1038/bjc.2012.262
11.    Assi WT. Moualla N. Ibrahim A. Prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among hemodialysis(HD) patients in Aleppo city, Syria. Research Journal of Pharmacy and Technology 2017; 10(5): 1301-1304. DOI: 10.5958/0974-360X.2017.00230.X
12.    World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. World Health Organization; 2016.
13.    Nurtjahyani SD. Probojati RT. Ansori ANM. Amin M. Handajani R. Haplotype Network Analysis and Phylogenetic Tree Construction of Hepatitis C Virus (HCV) Isolated from Tuban, Indonesia. Research Journal of Pharmacy and Technology. 2021; 14(8):4231-5. DOI: 10.52711/0974-360X.2021.00734
14.    Abass YA. Al-Husseiny KR., Kareem AA. Epidemiology of Hepatitis HBV and HCV at Thi-Qar Province –Iraq. Al-Qadisiyah Medical Journal. 2008; 4(5): 154-165.
15.    Hamdane H. Harfouch RM. Hepatitis B and C among blood donors in Tartous city, Syria. A Retrospective study. Research Journal of Pharmacy and Technology. 2021; 14(1):442-444. DOI: 10.5958/0974-360X.2021.00080.9
16.    Tarky AM, Akram WA, Al-Naaimi AS, Omer AR. Epidemiology of viral hepatitis B and C in Iraq: a national survey 2005-2006. Zanco Journal of Medical Sciences 2013; 17(1): 370-380. DOI: https://doi.org/10.15218/zjms.2013.0017
17.    Jasim. HS. Molecular detection and DNA Methylation of HBV in a group of Iraqi patients with Hepatocellular Carcinoma. Research Journal of Pharmacy and Technology 2019; 12(9):4489-4492. DOI: 10.5958/0974-360X.2019.00773.X
18.    National Center for Health Statistics. NHANES 1999–2004. http://www. cdc. gov/nchs/abou t/major/nhanes /datalink.htm. Accessed 12 May 2008.
19.    Akbar N. Basuki B. Garabrant DH. Sulaiman A. Noer HS.  MULYANTO. Ethnicity, socioeconomic status, transfusions and risk of hepatitis B and hepatitis C infection. Journal of Gastroenterology and Hepatology. 1997; 12(11): 752-757. doi: 10.1111/j.1440-1746.1997.tb00365.x.
20.    Ibraheem AM. Mohiadeen FA. Babakir-Mina M. Prevalence, Knowledge and practices of HBC&HCV among patients undergoing surgery in Sulaimani City. Journal of Rare Disorder Diagnosis and Therapy. 2016; 2: 6. doi: 10.21767/2380-7245.100053
21.    Hussein NR. Haj SM. Almizori LA. Taha AA. The prevalence of hepatitis B and C viruses among blood donors attending blood bank in Duhok, Kurdistan region, Iraq. International Journal of Infection. 2017; 4(1): e39008. doi: 10.17795/iji-39008
22.    Najim OA. Hassan MK. Prevalence of hepatitis C virus seropositivity among multitransfused patients with hereditary anemias in Basra, Iraq. Iraq Joural of Hematology. 2018; 7(1): 39-44. DOI:10.4103/ijh.ijh_41_17
23.    CDC. Viral hepatitis—statistics and surveillance. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/hepatitis/statistics/
24.    Harris AM. Iqbal K. Schillie S. Britton J. Kainer MA. Tressler S. Vellozzi C. Increases in acute hepatitis B virus infections—Kentucky, Tennessee, and West Virginia, 2006–2013. Morbidity and Mortality Weekly Report. 2016; 65(3): 47-50. doi: 10.15585/mmwr.mm6503a2.
25.    Eissa MS. Fayed AS. Hegazy MA. Kamel EB. Spectrophotometric analysis for simultaneous determination of the new Antiviral drug combination: Daclatasvir/Sofosbuvir in their pure form and Pharmaceutical Preparation. Research Journal in Pharmacy and Technology 2020; 13(12):5939-5946. DOI: 10.5958/0974-360X.2020.01037.9
26.    Paboriboune P. Vial T. Chassagne F. Sitbounlang P. et al. A seven-year retrospective study on the surveillance of hepatitis B in Laos. International Journal of Hepatology. 2018; 2018. https://doi.org/10.1155/2018/9462475
27.    Yasaswini RS. Annapurna MM. Sheela AS. New stability indicating RP-UFLC method for the determination of Trifluridine – A potent antiviral drug. Research Journal of Pharmacy and Technology 2020; 13(6): 2881-2885. DOI: 10.5958/0974-360X.2020.00514.4
28.    Mueller H. Wildum S. Luangsay S. Walther J. et al. A novel orally available small molecule that inhibits hepatitis B virus expression. Journal of Hepatology. 2018; 68(3): 412-20. doi: 10.1016/j.jhep.2017.10.014
29.    Singh L. Indermun S. Govender M. Kumar P. et al. Drug delivery strategies for antivirals against hepatitis B virus. Viruses. 2018; 10(5): 267. doi: 10.3390/v10050267
30.    Kim GA. Lim YS. An J. Lee D. et al. HBs Ag seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014; 63(8): 1325-1332. doi: 10.1136/gutjnl-2013-305517.
31.    Seto WK. Cheung KS. Wong DK. Huang FY. et al. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. Journal of gastroenterology. 2016; 51(5): 487-495. doi: 10.1007/s00535-015-1128-2.
32.    Perrillo RP. Martin P., Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA. 2015; 313(16): 1617-1618. doi:10.1001/jama.2015.2571
33.    Di Bisceglie AM. Lok AS. Martin P. Terrault N. et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: just the tip of the iceberg?. Hepatology. 2015; 61(2): 703-711. doi: 10.1002/hep.27609
34.    Akhilesh Upgade, Nilkanth Faldu , Kaleeswaran B. Insilico Analysis of non-Structural Protein (NS4b) from DENV-2 Indian Strain for Antiviral Drug Discovery. Research Journal in Pharmacy and Technology 2018; 11(4):1671-1676. DOI: 10.5958/0974-360X.2018.00311.6
35.    Mallet V. van Bömmel F. Doerig C. Pischke S. et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). The Lancet infectious diseases. 2016; 16(5): 606-617. doi: 10.1016/S1473-3099(16)00118-3.
36.    Perrillo RP. Gish R. Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015; 148(1): 221-244. doi: 10.1053/j.gastro.2014.10.038
37.    European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Journal of Hepatology. 2012; 57(1): 167-185.
38.    Liu J, Yang HI, Lee MH, Lu SN, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut. 2014; 63(10): 1648-1657.
39.    De Clercq. Férir G. Kaptein S. Neyts J. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses. 2010; 2(6): 1279-1305. doi:10.3390/v2061279
40.    European Association for The Study Of The Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology. 2017 Aug; 67(2): 370-398.
41.    Fadhil L. Saad AM. Al-Marzoqi AH. Shalan AA. et al. Genetic Study for the Role and Predictive Consequence of Certain Cytokines in Hepatitis B Iraqi Patients. Journal of Global Pharma Technology. 2017; 9(9): 75-83.
42.    Wang Y. Liu S. Chen Y. Zheng S. et al. Delayed reduction of hepatitis B viral load and dynamics of adefovir-resistant variants during adefovir plus entecavir combination rescue therapy. International Journal of Medical Sciences. 2015; 12(5): 416. doi:10.7150/ijms.11687

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available